Sotheby's BID
Sotheby's Board has presided over a 42% EPS collapse despite global wealth tailwinds; electing Third Point's three nominees can restore owner perspective and more than double pro-forma EPS.
Thesis
Third Point owns ~9.6% of Sotheby's and argues the Company has squandered a decade of structural tailwinds under a complacent, tenured board. Despite ultra-HNWI wealth rising 9% and luxury consumption up 28% versus 2007, Sotheby's revenue is down 6%, expenses are up 2%, and EPS has collapsed 42% from $3.25 to $1.88. Directors own just 0.87% of the company, average 8.9 years of tenure, and rapidly adopted a discriminatory poison pill two days after Third Point's public letter. Third Point nominates Daniel Loeb, Harry Wilson, and Olivier Reza (collectively owning nearly 10%) to three seats on the 12-director board to curb fractional commissions, overhaul CEO pay, accelerate secured lending and private sales, and instill an owner's perspective. Pro forma analysis shows conservative operational fixes could more than double EPS to $4.17.
SCQA
Sotheby's is one of two leading global auction houses (~46% share vs. Christie's), founded in 1744, operating 90 locations across 40 countries and 70 collecting categories, serving the top of a growing ultra-HNWI luxury market.
Despite structural tailwinds, EPS has fallen 42% since 2007 as revenue declined 6% and expenses rose 2% under a board owning only 0.87% with 8.9 years average tenure, which adopted a discriminatory poison pill to block Third Point.
Elect Third Point's three Shareholder Slate nominees — Daniel Loeb, Harry Wilson, and Olivier Reza — to the 12-seat board to drive expense discipline, governance reform, and growth in private sales, secured lending, and brand extension.
Modest, conservative improvements — a 100bp auction-commission-margin uplift plus 10% expense reduction — would more than double EPS from $1.94 to $4.17 pro forma, closing the gap to historical earnings power.
The three reasons
- 1
EPS collapsed 42% versus 2007 peak despite ultra-HNWI wealth +9% and luxury consumption +28%
- 2
Directors own just 0.87% with 8.9-year avg tenure; Board adopted discriminatory poison pill
- 3
Modest operational fixes could more than double EPS from $1.94 to $4.17 pro forma
Primary demands
- Elect Third Point's three nominees (Daniel Loeb, Harry Wilson, Olivier Reza) to the 12-member Board
- Redeem the discriminatory poison pill adopted two days after Third Point's public letter
- Curtail the unchecked use of fractional auction commissions
- Overhaul CEO compensation structure and improve transparency on performance metrics
- Deepen cost savings beyond the nominal $22 million program (mostly marketing cuts)
- Articulate a long-term growth strategy across auctions, private sales, secured lending, and brand extension
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Precedents cited
- Yahoo! (Loeb on board May 2012-July 2013, stock +85%)
- CF Industries
- Murphy Oil
- Bloomberg article 'Activist Investors are Good for the Stock Price' (April 2014)
Notable slides (6)
Notes
Classic proxy-fight deck preceding the May 6, 2014 Sotheby's annual meeting. Strong SCQA architecture: situation (leading auction house), complication (EPS -42% despite tailwinds), resolution (elect three-person Shareholder Slate), reward (pro forma EPS more than doubles). Notable rhetorical devices: (1) p.15 uses Munch's 'The Scream' painting as visual punchline for the 42% EPS collapse — an unusually witty flourish for an institutional deck given Sotheby's own auction-house subject matter; (2) p.27 closes with a bold typographic 'A Better BID!' play on the ticker; (3) p.6 timeline pairs Third Point's actions with Sotheby's defensive responses — strong before/after framing showing the value of shareholder pressure; (4) p.7 explicitly rebuts management's 'misdirection campaign' by quoting Gabelli and NYT in full context. Third Point filed suit in Delaware Chancery on March 25 challenging the poison pill. Stake: 9.6%. Campaign ultimately resulted in a settlement: Sotheby's agreed to add Loeb, Wilson, and Reza to the board, redeemed the pill, and CEO Ruprecht stepped down in 2014-2015.